Teva Pharmaceutical Industries Ltd.

Proxy Solicitation & Information Statement • Apr 20, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐

Check the appropriate box:

- ☐ Preliminary Proxy Statement

• ☒ Definitive Additional Materials
• ☐ Soliciting Material under §240.14a-12

☐ Confidential, For Use of the Commission ☐ Definitive Proxy Statement Only (as permitted by Rule 14a-6(e)(2))

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

• ☒ No fee required.
• ☐ Fee paid previously with preliminary materials.

☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

The following communication was sent to certain registered holders of its American Depositary Shares by or on behalf of Teva Pharmaceutical Industries Limited:

Important Notice Regarding the Availability of Proxy Materials for the Shareholder Meeting to be Held on June 15, 2023

Under Securities and Exchange Commission rules, you are receiving this notice that the proxy materials for the annual shareholders' meeting are available on the instructions below to view the materials and vote online or request a copy. The items to be voted on of the annual meeting are on the reverse side. Your vote is important!

This is not a votable ballot. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information the proxy materials before voting. The notice of annual meeting of shareholders and annual report to shareholders are available at:

www.investorvote.com/teva

27

Easy Online Access - View your proxy materials and vote.

Step 1: Go to www.investorvote.com/teva.

Teva Pharmaceutical Industries Limited Shareholder Meeting Notice

• Step 2: Click on the icon on the right to view meeting materials.
• Step 3: Return to the investorvote.com window and follow the instructions on the screen to log in.
• Step 4: Make your selections as instructed on each screen for your delivery preferences.

Step 5: Vote your shares.

When you go online, you can also help the environment by consenting to receive electronic delivery of future materials.

Obtaining a copy of the Proxy Materials - If you want to receive a copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. Please make your request as instructed on the reverse side on or before May 25, 2023 to facilitate timely delivery. Unless requested, you will not otherwise receive a paper or email copy.

03T87B

2 N O T

Shareholder Meeting Notice

Teva Pharmaceutical Industries Limited's Annual Meeting of Shareholders will be held on Thursday, June 15, 2023 at 4:00 p.m. (local time), 9:00 a.m. (Eastern time), at Teva's Executive Offices, 124 Dvora HaNevi'a Street, Tel Aviv, 6944020, Israel (the "Annual Meeting").

Proposals to be voted on at the meeting are listed below along with the Board of Directors' recommendations.

Teva's Board of Directors recommends that you vote FOR all proposals:

• 1. Election of Directors
  2. A Dr. Sol J. Barer
  3. B. M. Braverman-Blumenstyk
  4. Janet S. Vergis C.
• 1. To approve, on a non-binding advisory basis, the compensation for Teva's named executive officers.
• 1. To appoint Kesselman, a member of PricewaterhouseCoopers International Ltd., as Teva's independent registered public accounting firm until Teva's 2024 annual meeting of shareholders.

In addition, shareholders will consider Teva's annual consolidated financial statements for the year ended December 31, 2022.

PLEASE NOTE - YOU CANNOT VOTE BY RETURNING THIS NOTICE. To vote your shares you must go online or request a paper copy of the proxy materials to receive a proxy card.

If you wish to vote at the Anual Meeting through the online meeting platform, you must present your Teva ADSs for cancellation and withdrawal of the corresponding Teva ordinary shares in time to be a shareholder of Teva as of the record date on May 8, 2023.

PLEASE NOTE: In order for your ADS votes to be counted, you must be an ADS holder as of May 8, 2023.

1

Here's how to order a copy of the proxy materials and select delivery preferences:

Current and future delivery requests can be submitted using the options below.

If you request an email copy, you will receive an email with a link to the current meeting materials.

PLEASE NOTE: You must use the number in the reverse side when requesting a copy of the proxy materials.

• Internet Go to www.investorvote.com/teva.
• Phone Call us free of charge at 1-866-641-4276.
• Email Send an email to investorvote@computershare.com with "Proxy Materials Teva Pharmaceutical Industries Limited" in the subject line. Include your full name and address, plus the number located bar on the reverse side, and state that you want a paper copy of the meeting materials.

To facilitate timely delivery, requests for a paper copy of proxy materials must be received by May 25, 2023.

The following communication was sent to certain beneficial holders of its American Depositary Shares by or on behalf of Teva Pharmaceutical Industries Limited:

You invested in TEVA PHARMACEUTICAL INDUSTRIES LIMITED and it's time to vote!

You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy material for the shareholder meeting to be held on June 15, 2023.

Get informed before you vote

View the Form 10-K, Notice & Proxy Statement online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 25, 2023. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email сору.

"If you choose to vote these shares in person at the mess to "legal proxy." To do so, please follow the instructions at www.Proxylote.com or request a paper copy of the materials, which will contain the appropriate instructions. Please for any special requirements for meeting attendance.

Vote at www.ProxyVote.com

THIS IS NOT A VOTABLE BALLOT

This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters.

TEVA PHARMACEUTICAL INDUSTRIES LIMITED 2023 Annual Meeting Vote by June 13, 2023 11:59 PM ET

Board Voting Items Recommends Election of Directors 1. Nominees: 1A Dr. Sol J. Barer OFor 18 M. Braverman-Blumenstyk 7 For 1C Janet S. Vergis For 2 To approve, on a non-binding advisory basis, the compensation for Teva's named executive officers. 9For 3 To appoint Kesselman and Kesselman, a member of PriceWaterhouseCoopers International Ltd., as Teva's 9 For

NOTE: Such other business as may properly come before the meeting or any adjournment thereof. In addition, shareholders will consider Teva's annual consolidated financial statements for the year ended December 31, 2022. The Annual Meeting will be held at 4:00 PM IST / 9:00 AM EST. Shareholders will have the option to listen to the Annual Meeting through an audio webcast. Please check the meeting materials for additional details.

independent registered public accounting firm until Teva's 2024 annual meeting of shareholders.

The following communication was sent to certain beneficial holders of its ordinary shares by Teva Pharmaceutical Industries Limited:

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

2023 ANNUAL MEETING OF SHAREHOLDERS June 15, 2023 4:00 p.m. (Israel time) At Teva's Executive Offices 124 Dvora HaNevi'a Street Tel Aviv, 6944020 Israel

Participation instructions for the Teva Pharmaceutical Industries Limited 2023 Annual Meeting of Shareholders are available in the proxy statement which can be viewed at www.tevapharm.com/2023proxymaterials.

Important Notice Regarding the Availability of Proxy Materials for the Shareholder Meeting to be Held on June 15, 2023.

Notice is hereby given that the 2023 Annual Meeting of Shareholders (the "meeting") of Teva Pharmaceutical Industries Limited ("Teva") will be held at 124 Dvora HaNevi'a Street, Tel Aviv, 6944020, Israel on June 15, 2023 at 4:00 p.m. (Israel time).

This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. This is not a form for voting.

The Notice of Annual Meeting of Shareholders and Proxy Statement and Annual Report are available at www.tevapharm.com/2023proxymaterials.

If you want to receive a paper copy or an e-mail with links to the electronic materials, you must request one. There is no charge to you for requesting a copy. Please make your request for a copy as instructed below on or before May 25, 2023 to facilitate timely delivery. Unless requested, you will not otherwise receive a paper or email copy.

Matters intended to be acted upon at the meeting are listed below.

• 1. To appoint the following persons: Dr. Sol J. Barer, Michal Braverman-Blumenstyk and Janet S. Vergis to serve on the Board of Directors until our 2026 annual meeting of shareholders.
• 1. To approve, on a non-binding advisory basis, the compensation for Teva's named executive officers.
• 1. To appoint Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as Teva's independent registered public accounting firm until Teva's 2024 annual meeting of shareholders.

In addition, shareholders will consider Teva's annual consolidated financial statements for the year ended December 31, 2022.

The Board of Directors recommends that you vote FOR all proposals.

To request paper copies of the proxy materials, which include the proxy card, proxy statement and annual report, please contact us via:

• Telephone – Call our proxy solicitor, MacKenzie Partners, Inc., toll free within the U.S. at +1 (800) 322-2885 or outside the U.S. at + 1 (212) 929-5500. In Israel, call us at +972 (3) 914-8262.

• Email Send us an email at TevaIR@tevapharm.com or send an email to our proxy solicitor, MacKenzie Partners, Inc., at proxy@mackenziepartners.com, with "Teva Materials Request" in the subject line. The email must include:
• Your preference to receive printed materials via mail -or- to receive an email with links to the electronic materials.
• If you choose email delivery you must include the email address.
• If you would like this election to apply to delivery of material for all future meetings, write the word "Permanent".

In order to ensure timely delivery, you must request the information no later than May 25, 2023.